SCHEMBL4473255

SCHEMBL4473255

O=C(CCl)Nc1c(Cl)cccc1CO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
LMNA P02545 6/20 0.51
SMN1; SMN2 Q16637 6/20 0.49
NPSR1 Q6W5P4 1/20 0.43
PTGS1 P23219 2/20 0.42
PTGS2 P35354 2/20 0.42
TTR P02766 2/20 0.42
AKR1B10 O60218 1/20 0.42
UGT1A9 O60656 1/20 0.42
TRPA1 O75762 1/20 0.42
ABCB11 O95342 1/20 0.42
MT-CO2 P00403 1/20 0.42
ALB P02768 1/20 0.42
CXCL8 P10145 1/20 0.42
UGT1A6 P19224 1/20 0.42
UGT1A1 P22309 1/20 0.42
CXCR1 P25024 1/20 0.42
ADRA1A P35348 1/20 0.42
AGTR2 P50052 1/20 0.42
NR1I3 Q14994 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7291906 0.86 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2NPSR1MEN1
SCHEMBL14416594 0.85 TSHR (0.46) ALDH1A1PTGS1PTGS2TTRAKR1B10
SCHEMBL4472759 0.80 LMNA (0.46) ALDH1A1LMNASMN1; SMN2NPSR1PTGS1
SCHEMBL12512366 0.79 POLB (0.45) ALDH1A1LMNAPTGS1PTGS2TTR
SCHEMBL11274921 0.78 SMN1; SMN2 (0.54) ALDH1A1LMNASMN1; SMN2NPSR1TEAD1
SCHEMBL5528418 0.78 ALDH1A1 (0.66) ALDH1A1LMNASMN1; SMN2NPSR1PTGS2
SCHEMBL15619469 0.78 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2NPSR1MEN1
SCHEMBL3221540 0.78 PDK1 (0.51) PTGS1PTGS2TTRAKR1B10UGT1A9
SCHEMBL2211292 0.78 PDK1 (0.51) ALDH1A1LMNANPSR1PTGS1PTGS2
SCHEMBL6691256 0.77 ALDH1A1 (0.51) ALDH1A1LMNASMN1; SMN2PTGS2TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622473-B2 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-24 US disclosed
US-7622473-B2 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-24 US disclosed
US-7622473-B2 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites BRISTOL-MYERS SQUIBB COMPANY (US) 2009-11-24 US disclosed
EP-1863807-A1 'N-(2-CHLORO-6-METHYLPHENYL)-2-ÝÝ6-Ý4-(2-HYDROXYETHYL)-1-PIPERAZINYL¨-2-METHYL-4-PYRIMIDINYL¨AMINO¨-5-THIAZOLECARBOXAMIDES METABOLITES Brystol-Myers Squibb Company (US) 2007-12-12 EP disclosed
WO-2007106879-A2 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-20 WO disclosed
WO-2007106879-A2 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-20 WO disclosed
US-20070219370-A1 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2007-09-20 US disclosed
US-20070219370-A1 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2007-09-20 US disclosed
US-20070219370-A1 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF BRISTOL-MYERS SQUIBB COMPANY 2007-09-20 US disclosed
US-20060211705-A1 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 US disclosed
WO-2006099474-A1 'N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO]-5-THIAZOLECARBOXAMIDES METABOLITES BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219370-A1 PROCESS FOR PREPARING N-(2-CHLORO-6-METHYLPHENYL)-2-[[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PYRIMIDINYL]AMINO] -5-THIAZOLECARBOXAMIDE AND RELATED METABOLITES THEREOF UGT1A6, PAH, CYP2B6 ALDH1A1 96/4885LMNA 2000/4885SMN1; SMN2 1559/4885
US-20060211705-A1 'N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites IL2, TPMT, HNMT ALDH1A1 239/4885LMNA 3510/4885SMN1; SMN2 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.